Durable lipid-lowering beyond 10 years with lomitapide in homozygous familial hypercholesterolemia: A real-world experience in Taiwan
Journal of Clinical Lipidology · 2026
DOI: 10.1016/j.jacl.2026.08.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2026. Verfasst von Chao-Feng Lin und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, College of Medicine, MacKay Medical University, New Taipei City, Taiwan (Lin); Division of Cardiology, Department of Internal Med…. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II, Benzimidazoles, Homozygote, Anticholesteremic Agents. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Mackay Memorial Hospital, Shin Kong Wu Ho Su Memorial Hospital.
Abstract (Originalsprache)
BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening disorder characterized by extremely elevated low-density lipoprotein cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease (ASCVD). OBJECTIVE: This study aimed to report real-world outcomes of lomitapide, an LDL receptor-independent microsomal triglyceride transfer protein inhibitor, with follow-up beyond 10 years in an underreported East Asian population. METHODS: This retrospective study at a tertiary center in Taiwan included genetically confirmed patients with HoFH treated with lomitapide since 2013. Clinical characteristics, longitudinal lipid profiles, hepatic transaminases, liver magnetic resonance imaging for hepatic steatosis, carotid ultrasonography for intima-media thickness, and ASCVD events were reviewed through December 2025. RESULTS: Six patients with HoFH (mean age, 28.7 ± 18.2 years) were analyzed. After lomitapide initiation, 1 patient discontinued lomitapide early because of elevated hepatic transaminase. Four patients received lomitapide treatment for more than 10 years (mean follow-up, 140.8 ± 2.9 months). In this long-term cohort, LDL-C decreased from 264.0 ± 97.3 mg/dL at baseline to 141.5 ± 136.9 mg/dL at the last measurement (mean reduction, 55.8% ± 27.3%) and to 54.0 ± 28.6 mg/dL at nadir (maximal reduction, 80.0 ± 6.1%). Three patients (75%) achieved LDL-C
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, College of Medicine, MacKay Medical University, New Taipei City, Taiwan (Lin); Division of Cardiology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan (Lin); Institute of Ce…
- Department of Cardiology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan (Wang).
- Division of Cardiology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan (Charng). Electronic address: mjcharng@vghtpe.gov.tw.
Förderung
- Mackay Memorial Hospital
- Shin Kong Wu Ho Su Memorial Hospital
Zitieren
APA
Lin, C. F., Wang, W. H., & Charng, M. J. (2026). Durable lipid-lowering beyond 10 years with lomitapide in homozygous familial hypercholesterolemia: A real-world experience in Taiwan. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2026.08.015
Vancouver
Lin CF, Wang WH, Charng MJ. Durable lipid-lowering beyond 10 years with lomitapide in homozygous familial hypercholesterolemia: A real-world experience in Taiwan. Journal of Clinical Lipidology. 2026. doi:10.1016/j.jacl.2026.08.015
BibTeX
@article{Lin2026,
author = {Lin, Chao-Feng and Wang, Wen-Hwa and Charng, Min-Ji},
title = {Durable lipid-lowering beyond 10 years with lomitapide in homozygous familial hypercholesterolemia: A real-world experience in Taiwan},
journal = {Journal of Clinical Lipidology},
year = {2026},
doi = {10.1016/j.jacl.2026.08.015}
}
EUVIMED